SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray ...
BioFire Diagnostics won 510(k) clearance for its gastrointestinal panel for infectious diarrhea, following in the footsteps of the company's acquisition by French diagnostic giant bioMérieux.
This webinar will explore how using VIDAS® B•R•A•H•M•S PCT™ (procalcitonin) and BIOFIRE® FILMARRAY® Blood Culture Identification Panel results can optimize antimicrobial stewardship in patients with ...
Just a month out from being bought by French giant bioMérieux, BioFire Diagnostics took its FilmArray diagnostic system's new gastrointestinal option to the FDA for clearance, which the newly united ...
Background. Molecular syndromic diagnostic panels can enhance pathogen identification in the approximately 2–4 billion episodes of acute gastroenteritis that occur annually worldwide. However, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results